Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3641 (Ragwitek) in children with ragweed-induced rhinoconjunctivitis
NCT02478398Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2015
- Primary completion
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of SQ SLIT-tablet in allergic rhinitis (AR), sponsored by Merck & Co.. Started Jul 2015; status: completed.
02
Drugs
SQ SLIT-tablet
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02478398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478398.